

## Supplementary Online Content

Åsvold BO, Vatten LJ, Bjørø T, et al; Thyroid Studies Collaboration. Thyroid function within the normal range and risk of coronary heart disease: an individual participant data analysis of 14 cohorts. *JAMA Intern Med*. Published online April 20, 2015. doi:10.1001/jamainternmed.2015.0930.

**eTable 1.** Information on FT<sub>4</sub> and TPO Antibody Measurements and Types of CHD Event Data Available in Each Cohort

**eTable 2.** Baseline Characteristics by Thyrotropin Category

**eTable 3.** Sensitivity Analyses of the Association of Thyrotropin With Risk of CHD Outcomes

**eTable 4.** HRs of CHD Outcomes by Combinations of Thyrotropin Level and TPO Antibody Status at Baseline

**eTable 5.** HRs of CHD Outcomes per 1 pmol/L Higher FT<sub>4</sub> Level at Baseline, Overall and by Sex and Age

**eTable 6.** HRs of CHD Outcomes by Quartile Categories (Q) of FT<sub>4</sub> Levels at Baseline, Overall and by Sex and Age at Baseline

**eTable 7.** Sensitivity Analyses of the Association of FT<sub>4</sub> With Risk of CHD Outcomes

**eTable 8.** Sensitivity Analyses of the Association of FT<sub>4</sub> Quartile Categories With Risk of CHD Outcomes

**eFigure.** Hazard Ratios (HRs) of Coronary Heart Disease (CHD) Mortality, a First-Time CHD Event and a First-Time Hard CHD Event per 1 pmol/L Higher Free Thyroxine (FT<sub>4</sub>) Level at Baseline, Adjusted for Age, Sex and Smoking at Baseline

This supplementary material has been provided by the authors to give readers additional information about their work.

**eTable 1. Information on FT<sub>4</sub> and TPO antibody measurements and types of CHD event data available in each cohort.**

Cohort	FT <sub>4</sub> reference range	TPO antibody measurement; <sup>a</sup> criteria for positive test	CHD mortality – methods for ascertainment	Incident fatal and non-fatal CHD events - definitions	Incident fatal and non-fatal CHD events – methods for ascertainment	Available data on incident hard CHD events <sup>b</sup>
<b>Europe</b>						
Whickham Survey	NA	NA	Death certificates, postmortem reports, hospital or general practitioners' reports, ECG during the final recorded illness; causes of death coded with ICD-9 410-414	Fatal or non-fatal myocardial infarction, angina pectoris diagnosis by general practitioners, myocardial infarction on ECG, death certificates.	Self-reported history of angina or myocardial infarction confirmed by general practitioners or hospital records	No
Rotterdam Study	11-25 pmol/L <sup>c</sup>	Milena, DPC; positive if >10 IU/mL	Information from general practitioners and letters and discharge reports of medical specialists, coded independently by two study physicians and subsequently validated by a medical specialist (Leening MJ et al. Eur J Epidemiol 2012;27(3):173-185)	CHD mortality, non-fatal myocardial infarction, or coronary artery revascularization	Information from general practitioners and letters and discharge reports of medical specialists, coded independently by two study physicians and subsequently validated by a medical specialist (Leening MJ et al. Eur J Epidemiol 2012;27(3):173-185)	Yes
Leiden 85-Plus Study	13-23 pmol/L	NA	Causes of death obtained from Statistics Netherlands, where all national death certificates are coded by experts; ICD-10 I20-I25	Fatal and non-fatal myocardial infarction, angina pectoris	Interview, ECG and records of general practitioners	Yes

HUNT Study	8-20 pmol/L <sup>c</sup>	NA	Death certificates coded with ICD-9 410-414 or ICD-10 I20-I25	CHD mortality or hospitalization with myocardial infarction	Linkage with national cause of death registry and hospital records	Yes
EPIC-Norfolk Study	9-20 pmol/L	NA	Death certificates and hospital coding: causes of death coded with ICD-9-CM 410-414.	CHD mortality or hospital coding with diagnosis of CHD (ICD-9-CM 410-414)	Hospital discharge coding by data linkage with NHS central register	No
SHIP	8.3-18.9 pmol/L	AutoDelfia, PerkinElmer Life and Analytical Sciences, Wallac Oy; positive if >200 IU/mL	Death certificates from local health authority; independent validation of cause of death; review with another expert if disagreement; coded with ICD-10 I20-I25	NA	NA	No
PROSPER trial	12-18 pmol/L	NA	Trial participants reviewed every 3 months	CHD mortality or non-fatal myocardial infarction	Trial participants reviewed every 3 months	Yes
InCHIANTI	0.77-2.19 ng/dL	NA	Data from regional Mortality General Registry and death certificates at registry offices of the municipalities; ICD-9 410-14	CHD mortality, or hospitalization with CHD (ICD-9 410-414), or myocardial infarction or angina pectoris recorded at follow-up visits after 3, 6, and 9 years	Mortality General Registry and death certificates; hospital discharge coding; self-report, medication, documentation, ECG or Rose Angina Questionnaire score recorded at follow-up visits	Yes
<b>United States</b>						
Health, Aging, and Body Composition Study	0.8-1.8 ng/dL <sup>c</sup>	NA	Hospital records, death certificates, and other support documents reviewed by a panel of clinicians	Fatal or non-fatal acute myocardial infarction, angina pectoris, angioplasty of coronary arteries, or coronary artery	Interview, hospital records, and other support documents reviewed by a panel of clinicians	Yes

				surgery		
Cardiovascular Health Study	0.7-1.7 ng/dL	Elecsys 2010, Roche Diagnostics; positive if >37 IU/mL	Medical records, death certificates, autopsy reports, and coroners' reports reviewed by experts	Myocardial infarction, angina pectoris, coronary angioplasty, coronary artery surgery, atherosclerotic CHD mortality	Interview and hospital records reviewed by experts	Yes
MrOS	0.70-1.85 ng/dL	NA	Death certificates with ICD-9 410-414, adjudicated by a physician	NA	NA	No
<b>Australia</b>						
Busselton Health Study	9-23 pmol/L	Immulite 2000, Siemens; positive if ≥35 IU/mL	Registrar General's list of deaths: coded with ICD-9-CM 410-414	CHD mortality or hospital coding with a diagnosis of CHD	Hospital records: diagnoses coded with ICD-9 and ICD-10	No
<b>Asia</b>						
Nagasaki Adult Health Study	0.8-2.5 ng/dL	NA	Death certificates; causes of death coded with ICD-9-CM 410-414	NA	NA	No
<b>South America</b>						
Brazilian Thyroid Study	0.7-1.5 ng/dL	AutoDelfia, PerkinElmer Life and Analytical Sciences, Wallac Oy; positive if ≥35 IU/mL	Death certificates	NA	NA	No

Abbreviations: CHD, coronary heart disease; ECG, electrocardiogram; FT<sub>4</sub>, free thyroxine; ICD-9, International Classification of Diseases, Ninth Revision; ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification; ICD-10, International Classification of Diseases, Tenth Revision; NA, data not available; NHS, National Health Service; TPO, thyroid peroxidase

<sup>a</sup> Only reported for cohorts that measured TPO antibody levels in euthyroid participants.

<sup>b</sup> CHD mortality and myocardial infarction

<sup>c</sup> In these cohorts, FT<sub>4</sub> levels were not measured in people with thyrotropin within the reference range.

**eTable 2. Baseline characteristics by thyrotropin category.**

Characteristics	Serum thyrotropin concentration at baseline (mIU/L)			
	0.45-1.49	1.50-2.49	2.50-3.49	3.50-4.49
No. of participants	24,169	20,230	7734	3279
Age (years), mean (SD)	56.6 (14.3)	59.1 (13.6)	61.3 (13.2)	62.7 (13.1)
Women, %	57.4	59.0	61.6	66.2
Current smoking, % <sup>a</sup>	30.8	22.2	18.3	17.1
Body mass index (kg/m <sup>2</sup> ), mean (SD)	26.2 (4.0)	26.5 (4.2)	26.5 (4.4)	26.3 (4.5)
Diabetes, %	4.5	4.3	5.1	5.7
Systolic blood pressure (mmHg), mean (SD)	138 (22)	140 (22)	141 (23)	142 (23)
Total serum cholesterol (mg/dL), mean (SD)	231 (46)	234 (46)	232 (47)	232 (48)

<sup>a</sup> Not including the participants from the Nagasaki Adult Health Study, which classified participants as ever or never smokers.

**eTable 3. Sensitivity analyses of the association of thyrotropin with risk of CHD outcomes. HRs<sup>a</sup> of CHD outcomes per 1 mIU/L higher thyrotropin level at baseline.**

	CHD mortality		CHD events		Hard CHD events <sup>b</sup>	
	No. events/ participants	HR (95% CI)	No. events/ participants	HR (95% CI)	No. events/ participants	HR (95% CI)
Main analysis	1808 / 54,649	0.97 (0.90-1.04)	4666 / 48,875	1.00 (0.97-1.03)	2488 / 34,256	1.01 (0.96-1.06)
Excluding the first 2 years of follow-up	1631 / 53,740	0.96 (0.89-1.04)	3976 / 47,329	1.00 (0.96-1.03)	2055 / 33,068	1.01 (0.96-1.07)
With adjustment for BMI	1769 / 54,199	0.97 (0.91-1.03)	4590 / 48,429	0.99 (0.96-1.02)	2445 / 34,007	1.00 (0.95-1.05)
Excluding participants with diabetes	1586 / 52,376	0.97 (0.90-1.04)	4246 / 46,978	0.99 (0.96-1.03)	2199 / 32,615	1.01 (0.96-1.06)
Restricted to never-smokers	708 / 24,607	1.03 (0.93-1.14)	1751 / 21,842	0.99 (0.91-1.06)	978 / 15,170	1.01 (0.90-1.12)
Restricted to cohorts with information on thyroid medication during follow-up						
Including participants with thyroid medication during follow-up	748 / 15,516	0.93 (0.83-1.04)	1915 / 10,679	0.98 (0.93-1.02)	975 / 7063	1.00 (0.93-1.07)
Excluding participants with thyroid medication during follow-up	730 / 15,257	0.93 (0.83-1.05)	1858 / 10,497	0.97 (0.93-1.02)	935 / 6917	0.99 (0.92-1.07)
Restricted to cohorts that were identified through the systematic literature searches	1669 / 50,250	0.97 (0.89-1.05)	4243 / 45,413	1.00 (0.96-1.03)	2108 / 30,794	1.01 (0.96-1.06)
Excluding the SHIP cohort	1782 / 51,911	0.97 (0.90-1.04)		NA		NA
Excluding the Whickham Survey and the Leiden 85-Plus Study	1656 / 52,457	0.98 (0.91-1.06)	4302 / 46,683	1.01 (0.98-1.05)	2457 / 33,982	1.01 (0.97-1.06)

Abbreviations: BMI, body mass index; CHD, coronary heart disease; CI, confidence interval; HR, hazard ratio; NA, not applicable

<sup>a</sup> adjusted for age, sex and smoking at baseline unless otherwise noted

<sup>b</sup> CHD mortality or myocardial infarction

**eTable 4. HRs<sup>a</sup> of CHD outcomes by combinations of thyrotropin level and TPO antibody status at baseline.**

Thyrotropin level (mIU/L)	TPO antibody status	No. events / participants	HR	95% CI
<b>CHD mortality</b>				
0.45-2.49	Negative	299 / 4394	1.00	Reference
0.45-2.49	Positive	20 / 305	1.35	0.84-2.18
2.50-4.49	Negative	113 / 895	0.97	0.73-1.30
2.50-4.49	Positive	14 / 167	1.01	0.50-2.04
<b>CHD events</b>				
0.45-2.49	Negative	714 / 3217	1.00	Reference
0.45-2.49	Positive	42 / 212	0.91	0.53-1.57
2.50-4.49	Negative	249 / 875	0.88	0.70-1.11
2.50-4.49	Positive	35 / 154	1.03	0.49-2.17
<b>Hard CHD events<sup>b</sup></b>				
0.45-2.49	Negative	373 / 1795	1.00	Reference
0.45-2.49	Positive	19 / 138	0.44	0.08-2.40
2.50-4.49	Negative	174 / 726	0.87	0.56-1.35
2.50-4.49	Positive	25 / 101	1.76	0.66-4.72

Abbreviations: CHD, coronary heart disease; CI, confidence interval; HR, hazard ratio; TPO, thyroid peroxidase

<sup>a</sup> adjusted for age, sex and smoking at baseline

<sup>b</sup> CHD mortality or myocardial infarction

**eTable 5. HRs<sup>a</sup> of CHD outcomes per 1 pmol/L higher FT<sub>4</sub> level at baseline, overall and by sex and age.**

	CHD mortality			CHD events			Hard CHD events <sup>b</sup>		
	No. events/ participants	HR	95% CI	No. events/ participants	HR	95% CI	No. events/ participants	HR	95% CI
Overall	931 / 23,981	1.02	0.99-1.05	2575 / 18,213	1.03	1.00-1.07	896 / 5512	1.06	1.01-1.12
Sex									
Women	374 / 12,336	1.03	0.98-1.09	1059 / 9682	1.03	0.99-1.06	424 / 3018	1.06	1.00-1.13
Men	557 / 11,645	1.02	0.98-1.05	1516 / 8531	1.03	0.99-1.08	472 / 2494	1.05	0.97-1.14
<i>P</i> <sub>interaction</sub>		0.63			0.95			0.84	
Age at baseline									
<65 years	125 / 13,386	1.01	0.96-1.06	726 / 9502	0.99	0.92-1.05	15 / 226	1.17	0.99-1.39
65-79 years	660 / 9377	1.03	1.00-1.06	1606 / 7693	1.04	1.01-1.07	700 / 4297	1.05	1.00-1.10
≥80 years	146 / 1218	1.02	0.94-1.11	243 / 1018	1.04	0.97-1.12	181 / 989	1.05	0.97-1.14
<i>P</i> <sub>trend</sub>		0.86			0.08			0.54	

Abbreviations: CHD, coronary heart disease; CI, confidence interval; FT<sub>4</sub>, free thyroxine; HR, hazard ratio

<sup>a</sup> adjusted for age, sex and smoking at baseline

<sup>b</sup> CHD mortality or myocardial infarction



**eTable 6. HRs<sup>a</sup> of CHD outcomes by quartile categories (Q) of FT<sub>4</sub> levels at baseline, overall and by sex and age at baseline.**

FT <sub>4</sub> quartile categories	CHD mortality		CHD events		Hard CHD events <sup>b</sup>	
	No. events / participants	HR (95% CI)	No. events / participants	HR (95% CI)	No. events / participants	HR (95% CI)
Overall						
Q 1	247 / 6467	0.85 (0.66-1.10)	703 / 4868	0.87 (0.74-1.03)	220 / 1423	0.77 (0.62-0.97)
Q 2	192 / 5808	0.76 (0.57-0.99)	552 / 4450	0.73 (0.58-0.94)	196 / 1357	0.65 (0.41-1.01)
Q 3	245 / 5984	0.93 (0.74-1.17)	642 / 4506	0.86 (0.76-0.98)	237 / 1400	0.82 (0.65-1.03)
Q 4	247 / 5722	1.00 (Reference)	678 / 4389	1.00 (Reference)	243 / 1332	1.00 (Reference)
Women						
Q 1	91 / 3579	0.79 (0.55-1.12)	283 / 2730	0.89 (0.75-1.06)	105 / 774	0.80 (0.60-1.07)
Q 2	83 / 3090	0.72 (0.53-0.96)	241 / 2479	0.79 (0.66-0.95)	104 / 776	0.76 (0.53-1.09)
Q 3	91 / 3028	0.82 (0.61-1.09)	250 / 2347	0.81 (0.68-0.97)	97 / 747	0.75 (0.57-0.98)
Q 4	109 / 2639	1.00 (Reference)	285 / 2126	1.00 (Reference)	118 / 721	1.00 (Reference)
Men						
Q 1	156 / 2888	1.02 (0.77-1.35)	420 / 2138	0.92 (0.73-1.15)	115 / 649	0.78 (0.57-1.07)
Q 2	109 / 2718	0.86 (0.61-1.20)	311 / 1971	0.76 (0.56-1.04)	92 / 581	0.67 (0.39-1.16)
Q 3	154 / 2956	1.07 (0.80-1.42)	392 / 2159	0.93 (0.79-1.10)	140 / 653	0.92 (0.66-1.29)
Q 4	138 / 3083	1.00 (Reference)	393 / 2263	1.00 (Reference)	125 / 611	1.00 (Reference)
Age <65 years						
Q 1	39 / 3711	1.02 (0.54-1.91)	220 / 2653	1.22 (0.89-1.68)	4 / 78	0.36 (0.08-1.65)
Q 2	15 / 3252	0.48 (0.25-0.93)	168 / 2345	1.12 (0.82-1.53)	3 / 70	0.34 (0.07-1.62)
Q 3	41 / 3350	1.06 (0.46-2.45)	183 / 2323	1.03 (0.67-1.59)	4 / 44	0.60 (0.15-2.44)
Q 4	30 / 3073	1.00 (Reference)	155 / 2181	1.00 (Reference)	4 / 34	1.00 (Reference)
Age 65-79 years						
Q 1	165 / 2435	0.88 (0.69-1.13)	419 / 1957	0.86 (0.73-1.02)	168 / 1100	0.82 (0.66-1.01)
Q 2	149 / 2294	0.85 (0.68-1.06)	348 / 1883	0.73 (0.57-0.93)	163 / 1069	0.77 (0.53-1.12)
Q 3	168 / 2330	0.88 (0.70-1.11)	398 / 1935	0.87 (0.75-1.02)	188 / 1115	0.90 (0.72-1.13)
Q 4	178 / 2318	1.00 (Reference)	441 / 1918	1.00 (Reference)	181 / 1013	1.00 (Reference)

Age ≥80 years							
Q 1	43 / 321	0.75 (0.33-1.70)	64 / 258	0.80 (0.56-1.15)	48 / 245	0.82 (0.47-1.42)	
Q 2	28 / 262	0.74 (0.40-1.36)	36 / 222	0.53 (0.34-0.84)	30 / 218	0.61 (0.35-1.06)	
Q 3	36 / 304	0.78 (0.34-1.79)	61 / 248	0.78 (0.51-1.17)	45 / 241	0.74 (0.37-1.46)	
Q 4	39 / 331	1.00 (Reference)	82 / 290	1.00 (Reference)	58 / 285	1.00 (Reference)	

Abbreviations: CHD, coronary heart disease; CI, confidence interval; FT<sub>4</sub>, free thyroxine; HR, hazard ratio

<sup>a</sup> adjusted for age, sex and smoking at baseline

<sup>b</sup> CHD mortality or myocardial infarction

**eTable 7. Sensitivity analyses of the association of FT<sub>4</sub> with risk of CHD outcomes. HRs<sup>a</sup> of CHD outcomes per 1 pmol/L higher FT<sub>4</sub> level at baseline.**

	CHD mortality		CHD events		Hard CHD events <sup>b</sup>	
	No. events/ participants	HR (95% CI)	No. events/ participants	HR (95% CI)	No. events/ participants	HR (95% CI)
Main analysis	931 / 23,981	1.02 (0.99-1.05)	2575 / 18,213	1.03 (1.00-1.07)	896 / 5512	1.06 (1.01-1.12)
Excluding participants with FT <sub>4</sub> level outside the reference range	887 / 22,940	1.02 (0.98-1.07)	2470 / 17,447	1.03 (0.99-1.07)	825 / 5052	1.05 (0.99-1.12)
Excluding the first 2 years of follow-up	839 / 23,563	1.02 (1.00-1.04)	2179 / 17,570	1.03 (0.99-1.07)	684 / 5131	1.06 (1.00-1.12)
With adjustment for BMI	917 / 23,719	1.02 (0.99-1.05)	2528 / 17,955	1.03 (1.00-1.07)	881 / 5448	1.05 (1.00-1.10)
Excluding participants with diabetes	824 / 22,776	1.03 (0.99-1.06)	2342 / 17,384	1.03 (1.00-1.06)	761 / 4931	1.06 (1.01-1.11)
Restricted to never-smokers	336 / 11,024	1.02 (0.97-1.07)	974 / 8260	1.00 (0.97-1.04)	350 / 2301	1.03 (0.99-1.08)
Restricted to cohorts with information on thyroid medication during follow-up						
Including participants with thyroid medication during follow-up	551 / 12,041	1.03 (0.99-1.06)	1365 / 7210	1.05 (1.00-1.10)	896 / 5512	1.06 (1.01-1.12)
Excluding participants with thyroid medication during follow-up	533 / 11,837	1.03 (1.00-1.06)	1318 / 7083	1.05 (1.00-1.10)	858 / 5391	1.06 (1.01-1.12)
Restricted to cohorts that were identified through the systematic literature searches	792 / 19,583	1.02 (1.00-1.04)	2152 / 14,752	1.01 (0.98-1.04)	516 / 2051	1.10 (0.91-1.32)
Excluding the SHIP cohort	905 / 21,247	1.02 (0.99-1.06)		NA		NA
Excluding the Whickham Survey and the Leiden 85-Plus Study	908 / 23,710	1.02 (1.00-1.04)	2539 / 17,942	1.03 (0.99-1.06)	866 / 5241	1.05 (1.00-1.09)

Abbreviations: BMI, body mass index; CHD, coronary heart disease; CI, confidence interval; FT<sub>4</sub>, free thyroxine; HR, hazard ratio; NA, not applicable

<sup>a</sup> adjusted for age, sex and smoking at baseline unless otherwise noted

<sup>b</sup> CHD mortality or myocardial infarction

**eTable 8. Sensitivity analyses of the association of FT<sub>4</sub> quartile categories with risk of CHD outcomes.**

FT <sub>4</sub> quartile categories	CHD mortality		CHD events		Hard CHD events <sup>a</sup>	
	HR <sup>b</sup>	95% CI	HR <sup>b</sup>	95% CI	HR <sup>b</sup>	95% CI
Main analysis						
Q 1	0.85	0.66-1.10	0.87	0.74-1.03	0.77	0.62-0.97
Q 2	0.76	0.57-0.99	0.73	0.58-0.94	0.65	0.41-1.01
Q 3	0.93	0.74-1.17	0.86	0.76-0.98	0.82	0.65-1.03
Q 4	1.00	Reference	1.00	Reference	1.00	Reference
Excluding participants with FT <sub>4</sub> level outside the reference range						
Q 1	0.93	0.76-1.13	0.93	0.81-1.05	0.86	0.69-1.06
Q 2	0.79	0.59-1.04	0.78	0.62-0.97	0.72	0.48-1.10
Q 3	0.96	0.75-1.23	0.88	0.74-1.04	0.86	0.63-1.17
Q 4	1.00	Reference	1.00	Reference	1.00	Reference
Excluding the first 2 years of follow-up						
Q 1	0.88	0.68-1.13	0.95	0.83-1.10	0.87	0.70-1.07
Q 2	0.78	0.58-1.04	0.78	0.63-0.98	0.69	0.44-1.07
Q 3	0.93	0.73-1.19	0.93	0.82-1.05	0.88	0.71-1.09
Q 4	1.00	Reference	1.00	Reference	1.00	Reference
With adjustment for BMI						
Q 1	0.85	0.65-1.11	0.88	0.76-1.02	0.80	0.65-0.98
Q 2	0.78	0.59-1.02	0.75	0.59-0.95	0.68	0.44-1.03
Q 3	0.94	0.75-1.17	0.86	0.76-0.98	0.84	0.69-1.03
Q 4	1.00	Reference	1.00	Reference	1.00	Reference
Excluding participants with diabetes						
Q 1	0.89	0.69-1.17	0.93	0.81-1.07	0.82	0.66-1.01
Q 2	0.79	0.62-0.99	0.77	0.62-0.96	0.68	0.46-1.02
Q 3	0.99	0.81-1.20	0.91	0.81-1.02	0.87	0.71-1.07
Q 4	1.00	Reference	1.00	Reference	1.00	Reference
Restricted to never-smokers						
Q 1	0.79	0.56-1.10	0.98	0.80-1.20	0.84	0.55-1.29
Q 2	0.77	0.56-1.05	0.84	0.65-1.10	0.88	0.54-1.41
Q 3	0.78	0.56-1.09	0.83	0.66-1.05	0.82	0.49-1.39
Q 4	1.00	Reference	1.00	Reference	1.00	Reference
Restricted to cohorts with information on thyroid medication during follow-up						
Including participants with thyroid medication during follow-up						
Q 1	0.77	0.56-1.07	0.80	0.66-0.96	0.77	0.62-0.97
Q 2	0.71	0.49-1.04	0.66	0.46-0.95	0.65	0.41-1.01
Q 3	0.78	0.56-1.10	0.80	0.69-0.94	0.82	0.65-1.03
Q 4	1.00	Reference	1.00	Reference	1.00	Reference
Excluding participants with thyroid medication during follow-up						
Q 1	0.78	0.57-1.06	0.79	0.66-0.95	0.76	0.60-0.97



Q 2	0.72	0.49-1.07	0.64	0.45-0.93	0.63	0.40-0.98
Q 3	0.78	0.56-1.10	0.80	0.68-0.94	0.82	0.65-1.03
Q 4	1.00	Reference	1.00	Reference	1.00	Reference
Restricted to cohorts that were identified through the systematic literature searches						
Q 1	0.82	0.62-1.09	0.95	0.81-1.13	0.75	0.45-1.24
Q 2	0.71	0.50-1.01	0.85	0.68-1.07	0.58	0.16-2.16
Q 3	0.86	0.63-1.18	0.87	0.73-1.04	0.70	0.34-1.43
Q 4	1.00	Reference	1.00	Reference	1.00	Reference
Excluding the SHIP cohort						
Q 1	0.90	0.70-1.15				
Q 2	0.79	0.60-1.05				
Q 3	0.98	0.79-1.21				
Q 4	1.00	Reference	NA		NA	
With adjustment for systolic blood pressure and total serum cholesterol						
Q 1	0.88	0.67-1.18	0.92	0.80-1.07	0.81	0.64-1.03
Q 2	0.76	0.57-1.02	0.76	0.60-0.96	0.67	0.43-1.05
Q 3	0.97	0.76-1.23	0.90	0.80-1.01	0.86	0.70-1.08
Q 4	1.00	Reference	1.00	Reference	1.00	Reference
Excluding the Whickham Survey and the Leiden 85-Plus Study						
Q 1	0.92	0.74-1.14	0.90	0.76-1.06	0.81	0.65-1.01
Q 2	0.81	0.62-1.05	0.79	0.64-0.98	0.74	0.49-1.12
Q 3	0.99	0.81-1.20	0.89	0.79-1.01	0.88	0.72-1.07
Q 4	1.00	Reference	1.00	Reference	1.00	Reference


Abbreviations: BMI, body mass index; CHD, coronary heart disease; CI, confidence interval; FT<sub>4</sub>, free thyroxine; HR, hazard ratio; NA, not applicable

<sup>a</sup> CHD mortality or myocardial infarction

<sup>b</sup> adjusted for age, sex and smoking at baseline unless otherwise noted

eFigure. Hazard ratios (HRs) of coronary heart disease (CHD) mortality (A), a first-time CHD event (B) and a first-time hard CHD event (C) per 1 pmol/L higher free thyroxine (FT<sub>4</sub>) level at baseline, adjusted for age, sex and smoking at baseline.





The squares represent HRs from each cohort, and the lines represent 95% confidence intervals (CIs). The diamonds represent pooled HRs (with 95% CIs) from random-effects (D+L Overall) and fixed-effect (I-V Overall) meta-analysis.